Intrasense : and Guerbet sign a licensing and integration agreement for artificial intelligence in oncology medical imaging

Intrasense and Guerbet sign a licensing and integration agreement for artificial intelligence in oncology medical imaging

Montpellier, France, June 19, 2023 at 5:45 PM CET

Intrasense (FR0011179886 - ALINS), spécialiste des solutions logicielles d'imagerie médicale et concepteur de Myrian®, et Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announce the signature on June 19, 2023 of a license agreement to integrate and market Guerbet's artificial intelligence algorithms within Intrasense software platforms.

A partnership for artificial intelligence

This non-exclusive license agreement between Intrasense and Guerbet, announced in the press release of January 11, 2023, follows on from the collaboration agreement established in October 2022, which validated the technical feasibility of these technological integrations. This collaboration will enable both companies to capitalize on their complementary expertise in medical imaging software and artificial intelligence.

This agreement, negotiated on a fair and competitive basis ("at arm's length"), authorizes Intrasense to integrate Guerbet's artificial intelligence algorithms into its own software and to market them. Under the terms of the agreement, Intrasense will be responsible for the clinical validation, regulatory registration and marketing of products for which it will be the legal manufacturer.

Enhancing Intrasense's high value-added offering

Intrasense will integrate the algorithms developed by Guerbet into its Myrian offering, an advanced visualization solution for medical imaging, and its new intelligent oncology platform. Specializing in the detection of liver lesions, prostate cancer, pancreatic cancer and bone lesions, these algorithms are designed to improve diagnostic accuracy and efficiency. Their integration into routine clinical tools will facilitate oncology patient follow-up and therapeutic decision-making, helping to save lives.

This agreement is in line with Intrasense's strategy of enriching its product portfolio with AI algorithms, developed by the company itself or by various partners, and accelerating its growth momentum.

Guerbet's algorithms aim to respond to currently unmet medical needs, such as the early detection of pancreatic or liver cancer. This technological alliance between the

Press release

1/2

two groups will provide markets with innovative, high value-added solutions, and will enable Intrasense to pursue its expansion in existing markets and conquer new territories.

• This licensing agreement will enable us to integrate highly innovative, high- performance algorithms for pathologies that are both highly complex and of major public health importance. It testifies to our commitment to meeting the needs of healthcare professionals with differentiating, ever more innovative and tailored solutions » says Nicolas Reymond, CEO of Intrasense.
• We are very pleased with this agreement, which will bring to market products that combine Intrasense's expertise in ergonomics and advanced visualization with Guerbet's clinical relevance and rigorous development in artificial intelligence, with the aim of improving patient care in oncology » declares Nicolas François, SVP R&D at Guerbet and Chairman of the Board at Intrasense.

About Intrasense

A French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced visualization solution for radiology, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing a new platform

dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up.

A Guerbet Group subsidiary since June 2023, Intrasense continues to enhance its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

Learn more at www.intrasense.fr

About Guerbet

At Guerbet, we build lasting relationships to enable people to live better. This is our raison d'être. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices and digital and AI solutions for diagnostic and interventional imaging.

A pioneer in the field of contrast media for 95 years with more than 2,700 employees worldwide, we are constantly

Intrasense

Salomé Sylvestre

Communications officer

Phone : [phone]

[e-mail]

innovating and devote between 8% and 10% of our sales to research and development in five centers in France, Israel and the United States. Guerbet (GBT) is listed in compartment B of Euronext Paris and achieved a turnover of 732 million euros in 2021.

Learn more at www.intrasense.fr

NewCap

Thomas Grojean Financial Communication and investor relations Phone : [phone]

[e-mail]

Press release

2/2